32 results about "Fixed dose" patented technology

The invention relates to a pharmaceutical composition comprising a fixed dose combination of (a) Netupitant or salt or hydrate thereof, and (b) Palonosetron or salt or hydrate thereof, in a single pharmaceutical unit. The invention further relates to a method of preparing a pharmaceutical composition in the form of a tablet, the method comprising: (i) wet granulating a dry mixture comprising Netupitant or a salt or hydrate thereof, filler, a binder, a disintegrant, and optionally a surfactant and / or a lubricant, with a solution comprising Palonosetron or a salt or hydrate thereof, and optionally a surfactant and / or a binder, to produce granules, (ii) blending the granules with a lubricant, a disintegrant and a glidant, and optionally a filler, and (iii) compressing of the lubricated granules to produce a tablet. The invention further relates to the pharmaceutical composition for use in the treatment and / or prevention of nausea and / or vomiting, preferably in the treatment and / or prevention of acute or delayed nausea and vomiting associated with chemotherapy, such as highly or moderately emetogenic cancer chemotherapy, for example cisplatin cancer chemotherapy.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and chidaridine.

The present disclosure provides for fixed-dose combination formulations comprising flavoxate or a pharmaceutically acceptable salt thereof and at least one β3-adrenergic receptor agonist, along with methods of making and using the same to treat symptoms associated with prostate, bladder, urinary tract, and pelvic conditions.

A pharmaceutical composition in a fixed-dose combination is described, comprising: a) a dofetilide component; and b) a mexiletine component; wherein the dofetilide component and the mexiletine component are physically separated from each other, and a method for treating or preventing atrial fibrillation or related symptoms in a subject by administering such pharmaceutical composition to a subject in need, and a method for preparing such a fixed-dose combination product.

The application provides an intelligent postoperative analgesia method and device based on voice recognition control, and relates to the technical field of postoperative analgesia. The method comprises the following steps: initializing the analgesia infusion level of an analgesia pump as an intermediate level, wherein the analgesia pump is provided with multiple levels, and the levels are arranged in ascending order according to the analgesia infusion dose; the analgesia pump is activated by voice in response to the occurrence of discomfort symptoms of a patient, and the analgesia pump is controlled to inquire whether the patient has insufficient analgesia or excessive analgesia; if the patient feeds back insufficient analgesia, the analgesia pump is controlled to execute single-dose administration or to increase the analgesia infusion level; and if the patient feeds back excessive analgesia, the analgesia pump is controlled to suspend drug infusion or to reduce the analgesia infusion level. Through voice control and dynamic dose adjustment technology, convenient operation and individualized analgesia management are realized, the problems of insufficient analgesia or excessive analgesia caused by fixed dose setting in a traditional analgesia pump are avoided, the frequent intervention of medical staff is reduced, and the safety and effect of postoperative analgesia are improved.

The invention discloses a dose control method for a human body X-ray security inspection device, and the method comprises the steps: obtaining a height value (H) and a weight value (W) of a detected person before scanning, and calculating a weight-height ratio (R) of the detected person; calculating a target dose value Dtarget according to a formula Dtarget = D0 + K * R; the target dose value is compared with preset dose upper and lower limits (Dmax, Dmin) to determine a final emission dose (final dose value Dfinal). Personalized adjustment of the scanning dose is carried out according to the obesity degree (quantified through the weight-height ratio) of the detected person, and unnecessary radiation irradiation on the detected person with a thin and small body shape can be reduced; meanwhile, compared with traditional X-ray scanning with a fixed dose value, an image with a higher signal-to-noise ratio and clearer details can be obtained for an obese detected person, so that a security check person can identify dangerous articles possibly existing in the image, and the accuracy and safety of security check are improved.

Embodiments relate to systems comprising Active Wearable Medical Device (AWMD) with an osmotic chamber containing or configured to receive an osmotic agent, a permeability module for fluid ingress, and a drug chamber holding a drug. A compressible piston, positioned between the chambers, moves longitudinally as a whole during operation. The compressible piston advances toward the drug chamber when a valve opens, enabling drug release through one or more outlets, and retracts when the valve closes, driven by osmotic pressure. A valve module regulates this flow. The system also comprises a fluid chamber containing fluid and a semipermeable membrane coupling it to the AWMD. A channel connected to the drug outlets delivers the drug externally.

The present disclosure relates to a combination of abiraterone acetate and niraparib, free-dose and fixed-dose combinations of abiraterone acetate and niraparib, and methods of treatment of prostate cancer with said combinations.

Combination therapy comprising inalipase and a fixed-dose combination (PH FDC SC) of pertuzumab and trastuzumab for subcutaneous injection is provided for the treatment of HER2-positive cancer; and a method for treating PIK3CA-mutated HER2-positive (HER2+) locally advanced or metastatic breast cancer, the method comprising administering a therapeutically effective amount of inalipase and PH FDC SC.

The invention relates to a reuseable injection device (1) for ejecting a plurality of fixed doses of a liquid drug from a replaceable cartridge, wherein a piston rod arrangement (50) is divided into two separate parts, i.e., a washer part (52) and a rod part (51), the two parts being urged away axially from each other by a spring element (53). When a new cartridge assembly (20) is attached to housing structure (10), the washer part (52) of the piston rod arrangement (50) is moved proximally against the force of the spring element (53) by engagement with the plunger (42) inside the cartridge (40) thereby accumulating force in spring element (53). Upon mounting of an injection needle onto the cartridge assembly (20) the accumulated force urges the washer part (52) in the distal direction back to its initial position thus performing an automatic priming of the injection device (1).

The present invention relates to pharmaceutical compositions comprising fixed dose combinations of a DPP-4 inhibitor drug and / or a SGLT-2 inhibitor drug, and metformin XR, processes for the preparation thereof, and their use to treat certain diseases.

This disclosure provides pharmaceutical compositions comprising a fixed dose of a dimeric T cell modulatory proteins (DTMPs) comprising peptide-MHC complexes (pMHCs) that present a peptide other than a peptide of an HPV protein or a WT1 protein, and methods of treating an individual in need thereof by administering a fixed dose of a DTMP. The pharmaceutical compositions comprise a fixed dose of a DTMP, and the methods comprise administering a fixed dose of a DTMP to an individual regardless of the weight of the individual. Also provided are kits useful for administering a fixed dose of the DTMP.

The invention discloses an ICU (intensive care unit) medicine intelligent blending and information management system, which relates to the technical field of intelligent medical treatment and comprises a data acquisition module, a data integration module, a dose calibration module, a consumption analysis module and an inventory management module. Multi-modal physiological sign data of an ICU patient are collected in real time through the data collection module and preprocessed into standardized physiological sign data, the data integration module is connected with the electronic medical record system to extract clinical basic data and basic sign baseline data, and a unified diagnosis and treatment data set is formed through correlation and integration. The dosage calibration module calculates the adjusted individualized medication dosage and generates an individualized medication instruction on the basis of the unified diagnosis and treatment data set in combination with clinical medication specifications and physical sign fluctuation-dosage adjustment rules, so that the medication dosage is accurately matched with the individual characteristics of the patient and real-time illness state changes, medicine allocation better meets the diagnosis and treatment requirements of the ICU patient, and the diagnosis and treatment efficiency of the ICU patient is improved. And the limitation of a fixed dose scheme is avoided.

1. Name of the product in this design: Injection pen (blue and white). 2. Purpose of this design: It belongs to medical devices and is used for manual administration of drugs at a fixed dose. 3. The key design feature of this product is its shape. 4. The image or photograph that best illustrates the design's key points: a 3D model. 5. The design for which protection is sought includes color.

The present application relates to an inhalable liquid composition suitable for nebulization comprising a fixed dose combination comprising glycopyrronium, formoterol and budesonide for treating a pulmonary disorder(s). The present application also relates to a process for preparing such a composition comprising a fixed dose combination comprising glycopyrronium, formoterol and budesonide.

The present disclosure relates to a pharmaceutical composition comprising dapagliflozin and sitagliptin, and method of preparation thereof. More particularly, dapagliflozin is present as dapagliflozin propanediol monohydrate, and sitagliptin is present as sitagliptin phosphate monohydrate. Furthermore, the present disclosure provides methods including wet granulation, dry granulation and direct compression for preparing fixed dose composition(s). The fixed dose composition is available in solid oral dosage forms, such as a tablet, capsule or sachet, wherein the tablet can be monolayer or bilayer tablet. The said composition is uniform, effective, stable to simplify management regimens, enhance subject adherence, and provide sustained glycaemic control in management of Type 2 Diabetes Mellitus.

The invention provides a system and a method for dynamic verification of radiotherapy plans, and the system comprises a three-dimensional electric platform, a three-dimensional electric reference mark support, a control unit and a software control module, and the three-dimensional electric platform is provided with a universal clamp which is used for bearing and fixing a dose measurement device. The three-dimensional electric reference mark support is independently installed on one side of the three-dimensional electric platform and used for fixing a reference mark visible to X rays, and the control unit is electrically connected with the three-dimensional electric platform and the three-dimensional electric reference mark support and used for controlling the reference mark according to the mode selected by the software control module and a motion trail instruction sent by the software control module. The software control module is used for driving the three-dimensional electric platform and the three-dimensional electric reference mark bracket to move independently or cooperatively, and comprises a motion management module for generating a motion track instruction, a mode control module for providing switching of a dose verification mode and a system performance test mode, and a dose analysis module for analyzing by adopting a Gamma algorithm. The real physiological movement of the patient can be simulated, the composite error is separated, and the adaptability is high.

Described herein are methods and compositions, for example a fixed dose oral composition, for treating a TYK2-mediated neuroinflammatory disease or disorder, and / or a TYK2-mediated neurodegenerative disease or disorder. In some embodiments, the TYK2- mediated disorder neuroinflammatory disease is, for example, multiple sclerosis.

This disclosure provides pharmaceutical compositions comprising a fixed dose of a dimeric T cell modulatory proteins (DTMPs) comprising peptide-MHC complexes (pMHCs) that present an HPV peptide, and methods of treating an individual in need thereof by administering a fixed dose of a DTMP. The pharmaceutical compositions comprise a fixed dose of a DTMP, and the methods comprise administering a fixed dose of a DTMP to an individual regardless of the weight of the individual. Also provided are kits useful for administering a fixed dose of the DTMP.

The present invention relates to a fixed-dose pharmaceutical composition comprising (2S)-2-[(4,6- dimethylpyrimidin-2-yl)oxy]-3-methoxy-3,3-diphenylpropanoic acid or its pharmaceutically acceptable salt, ester, solvate, polymorph, enantiomer or mixture thereof and (6R,12aR)-6-(1,3-benzodioxol-5-yl)-2-methyl-2,3,6,7,12,12a-hexahydropyrazino[1',2':1,6]pyrido[3,4-b]in dole-1,4-dione or its pharmaceutically acceptable salt, ester, solvate, polymorph, enantiomer or mixture thereof, wherein the composition is further comprising one or more pharmaceutically acceptable excipients, and also a process for the preparation thereof.

Methods for treating chronic kidney disease and liver fibrosis in patients using a fixed-dose combination of zibotentan and dapagliflozin are disclosed.

The present invention relates to a method of treating asthma comprising administering as rescue medication a fixed-dose dry powder inhalation composition comprising fluticasone propionate and salbutamol sulfate in patients aged > 4 years on an as-needed (PRN) basis, wherein the fluticasone propionate is administered at a delivered dose of 22-59 micrograms per inhalation, the salbutamol sulfate is administered at a delivered dose of 92-124 micrograms per inhalation, and the treatment provides one or more of: an extended time to first severe clinical asthma exacerbation compared to salbutamol sulfate rescue treatment, a reduced total annualized systemic corticosteroid (SCS) exposure compared to salbutamol sulfate rescue treatment, a reduced annualized rate of severe clinical asthma exacerbations compared to salbutamol sulfate rescue treatment. Also provided is a fixed-dose dry powder inhalation composition and a dry powder inhaler for use in performing the method of the invention.

The present disclosure relates generally to pharmaceutical dosage forms comprising azacitidine and cedazuridine.

The present disclosure relates to combinations of obicetrapib and ezetimibe, or their salts, solvates or derivatives thereof. The disclosure further describes the use of ezetimibe and obicetrapib, e.g. in the form of a fixed dose combination product, for preparation of medicaments and method of treatment of subjects requiring reduction in LDL-cholesterol or those suffering from hyperlipidemia or mixed dyslipidemia.

The present invention relates to a composition comprising Mesdopetam alone or in combination with proton pump inhibitor which can be administered either separately i.e. by co-administration or in a fixed dose combination (FDC) in the treatment of gastrointestinal and related disorders. The present invention provides use of mesdopetam in the manufacture of a medicament for the treatment of gastrointestinal disorders in a subject in need thereof wherein the medicament is to be administered to the subject. The present invention also relates to a method of treating gastrointestinal diseases in a subject in need thereof comprising administering to the subject mesdopetam and pharmaceutical composition.

The utility model discloses a mouse drug delivery device, and belongs to the technical field of animal experiments. The device comprises a dosing box and a plurality of atomizers fixed on the dosing box, and further comprises a plurality of atomization cavities and a standing chamber which are formed in the dosing box, the atomization cavities correspond to the atomizers in position, the standing chamber is correspondingly located below the atomization cavities, and an isolation assembly is movably arranged between the atomization cavities in a penetrating mode. A glass plate and a timer are arranged on two sides of the dosing box; the isolation component is used for isolating and cooperating with a plurality of atomizers for drug administration, and atomized drugs with different concentrations are provided to act on mice in different standing chambers, so that the mice in the standing chambers have a good contrast effect, and the experimental result is more accurate and more scientific; continuous administration of a single atomizer is matched with fixed-point isolation through the isolation assembly, and the administration time of the standing chambers on the two sides can be controlled; therefore, experimenters can better understand the action mechanism of the medicine under different conditions, and the experiment accuracy is improved.

Methods for treating chronic kidney disease and liver fibrosis in patients using a fixed-dose combination of zibotentan and dapagliflozin are disclosed.

To provide a method for treating a human patient suffering from lung cancer, e.g., non-small cell lung cancer (NSCLC).SOLUTION: In one or more dosing cycles, the subject is administered anti-TIGIT antagonist antibodies at a fixed dose of about 30mg to about 1200mg every three weeks and anti-PD L1 antagonist antibodies at a fixed dose of about 80mg to about 1600mg every three weeks.SELECTED DRAWING: None

This disclosure provides pharmaceutical compositions comprising a fixed dose of a dimeric T cell modulatory proteins (DTMPs) comprising peptide-MHC complexes (pMHCs) that present a Wilms Tumor-1 (WT1) peptide, and methods of treating an individual in need thereof by administering a fixed dose of a DTMP. The pharmaceutical compositions comprise a fixed dose of a DTMP, and the methods comprise administering a fixed dose of a DTMP to an individual regardless of the weight of the individual. Also provided are kits useful for administering a fixed dose of the DTMP.

The invention relates to a spring driven multi-use fixed dose injection device with an End-of-Content (EoC) mechanism. A housing structure contains a volume of a liquid drug which is expelled in a predefined number of substantially equally sized dose volumes. Each dose volume is expelled automatically with the assistance of a spring which is loaded with a force sufficient to expel the full number of the predefined plurality of predetermined and equally sized dose volumes. Each dose volume is prepared and released by moving a drive element a predetermined axial distance in the proximal direction away from an initial position, followed by a rotation of the drive element by the force of the spring back to the initial position during which rotation the drive element rotates the piston rod to move helically. The End-of-Content mechanism determines how many times the drive element can be moved proximally and comprises a longitudinal track structure associated with the piston rod which has a free length defined by a proximal stop associated with the piston rod which stop prevents the drive element from moving an additional predetermined axial distance in the proximal direction required to prepare a subsequent predetermined dose volume after the predefined plurality of predetermined and equally sized dose volumes have been selected.